Jiaoze
+86-21-37318802
[email protected]
Sitemap |  RSS |  XML
English English
  • English English
  • Home
  • About Us
    • Company Profile
    • Development History
    • Corporate Culture
  • Products
    • Intermediates And APIs
      • Intermediate
      • Active Pharmaceutical Ingredient
    • Veterinary Drug Service
    • Cosmetics Ingredients
  • News
    • Industry News
    • Company News
  • R&D Services
  • Send Inquiry
  • Contact Us
Send Inquiry
Home Send Inquiry

Product Categories

  • Intermediates And APIs

    • Intermediate
    • Active Pharmaceutical Ingredient
  • Veterinary Drug Service

  • Cosmetics Ingredients

New Products
  • Shikimic Acid CAS 138-59-0
    Shikimic Acid CAS 138-59-0
  • (R)-3-Piperidinamine dihydrochloride CAS 334618-23-4
    (R)-3-Piperidinamine dihydrochloride CAS 334618-23-4
  • Creatine monohydrate CAS 6020-87-7
    Creatine monohydrate CAS 6020-87-7
  • Tetramethyluric acid CAS 2309-49-1 HPLC 60%
    Tetramethyluric acid CAS 2309-49-1 HPLC 60%
  • Berberine hydrochloride CAS 633-65-8
    Berberine hydrochloride CAS 633-65-8
All new products

Send Inquiry

Verify Code
Links:

    Contact Us

    • Address: No.688 Qiushi Road, Jinshan Wei Town, Shanghai, China
    • Phone: +86-21-37318802
    • E-mail: [email protected]

    Inquiry For Price list

    For inquiries about our products or pricelist, please leave your email to us and we will be in touch within 24 hours.

    Latest News

    • How CDMOs Are Accelerating Small Molecule Timelines: From API Synthesis to Commercial Scale-Up
      How CDMOs Are Accelerating Small Molecule Timelines: From API Synthesis to Commercial Scale-Up 2025/08/06

      CDMOs are accelerating small molecule timelines by offering integrated services from API synthesis to commercial scale-up. They use advanced technologies like PAT and real-time data monitoring to streamline development, reduce risk, and ensure regulatory compliance. With continuous manufacturing and digital supply chain integration, CDMOs provide strategic advantages in speed and scalability, transforming the pharmaceutical landscape.

    • Why Are 63% of Small Molecule CDMO Projects Delayed? Raw Material Sourcing & Regulatory Hurdles
      Why Are 63% of Small Molecule CDMO Projects Delayed? Raw Material Sourcing & Regulatory Hurdles 2025/07/08

      In 2025, delays in small molecule CDMO projects remain a persistent challenge—with 63% of programs failing to meet original timelines. Two recurring culprits stand out: raw material sourcing issues and evolving regulatory demands.

    Copyright © 2024 Shanghai Jiaoze Industrial Co., Ltd. - All Rights Reserved
    • Links
    • Sitemap
    • RSS
    • XML
    • Jiaoze Industrial
    • Jiaoze Industrial
    • Jiaoze Industrial
    • Jiaoze Industrial
    • Jiaoze Industrial